The Summer School addresses all medical topics towards building sustainable and co-created telemedicine systems in Western Balkan Countries. The WHO has issued a document outlining key strategic points for improving the […]

Recent advancements in artificial intelligence (AI) in health has sparked public debate on the extent to which technology, and more specifically generative AI, has the potential to infringe upon personal privacy and impact the health of populations. To explore this and other issues impacting current and future European Region health system landscapes, WHO/Europe is hosting the second WHO Symposium on the Future of Digital Health Systems in the European Region on 5–6 September.

The virtual meeting of beneficiary and affiliated entities will review the latest steps of the Joint Action and briefly present what is to come. Attendees belonging to 35 organisations from 16 different countries will exchange ideas and questions about the progress and outcomes of eCAN so far.

OpenLivingLab Days is the flagship annual event organized by the European Network of Living Labs (ENoLL). The event offers a unique platform for networking, exchanging best practices, and collaborating on cutting-edge projects and for reflecting on the latest trends and how to shape the future. eCAN WP8 members will talk about the project during the event.

It is expected that during the six months of the Spanish Presidency of the Council of the EU the processing will continue, presumably at first reading, of the proposal for the European Health Data Space Regulation. Among other aims, one of the effects of this project will be to promote personalised healthcare, through the provision of face-to-face and virtual services for patients, specifically adapted to their characteristics and health situation.

The conference will bring together a large number of high-level experts and stakeholders with different background and expertise, from different types of organisations and countries, including from outside Europe, to discuss challenges and opportunities in the field of genomic-based personalised medicine, as well as aspects not covered in research and funding.